[go: up one dir, main page]

PL1868614T3 - Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem - Google Patents

Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem

Info

Publication number
PL1868614T3
PL1868614T3 PL06748657T PL06748657T PL1868614T3 PL 1868614 T3 PL1868614 T3 PL 1868614T3 PL 06748657 T PL06748657 T PL 06748657T PL 06748657 T PL06748657 T PL 06748657T PL 1868614 T3 PL1868614 T3 PL 1868614T3
Authority
PL
Poland
Prior art keywords
progesterone
treatment
brain injury
dosage regimen
traumatic brain
Prior art date
Application number
PL06748657T
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellermann
Donald G Stein
David W Wright
Douglas W Lowery-North
Sarah Melissa Cutler
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of PL1868614T3 publication Critical patent/PL1868614T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
PL06748657T 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem PL1868614T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24
PCT/US2006/010797 WO2006102596A2 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone
EP06748657A EP1868614B1 (en) 2005-03-24 2006-03-24 Dosage regimen for the treatment of a traumatic brain injury with progesterone

Publications (1)

Publication Number Publication Date
PL1868614T3 true PL1868614T3 (pl) 2013-01-31

Family

ID=36987966

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06748657T PL1868614T3 (pl) 2005-03-24 2006-03-24 Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem
PL08167618T PL2030622T3 (pl) 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08167618T PL2030622T3 (pl) 2005-03-24 2006-03-24 Wskazanie dawkowania progesteronu w leczeniu urazowego uszkodzenia mózgu

Country Status (16)

Country Link
US (4) US20090221544A1 (pl)
EP (5) EP1871382B1 (pl)
JP (5) JP5394059B2 (pl)
AT (2) ATE520404T1 (pl)
AU (2) AU2006226811B2 (pl)
CA (2) CA2601715C (pl)
CY (2) CY1111478T1 (pl)
DE (1) DE602006020353D1 (pl)
DK (2) DK1868614T3 (pl)
ES (2) ES2392454T3 (pl)
HK (3) HK1112579A1 (pl)
HR (2) HRP20110198T1 (pl)
PL (2) PL1868614T3 (pl)
PT (2) PT2030622E (pl)
RS (1) RS52471B (pl)
WO (2) WO2006102596A2 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871382B1 (en) 2005-03-24 2011-08-17 Emory University Methods for the treatment of central nervous system injury via a tapered administration of progesterone
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2052724A1 (en) 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
AU2009219230A1 (en) 2008-02-26 2009-09-03 Emory University Steroid analogues for neuroprotection
CA2740628C (en) 2008-09-18 2018-05-01 Naurex, Inc. Nmda receptor modulators and uses thereof
US20110306579A1 (en) * 2009-01-30 2011-12-15 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP3689364A1 (en) 2010-02-08 2020-08-05 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
EP2701721A4 (en) * 2011-04-27 2015-12-16 Univ Northwestern METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER, MORBUS HUNTINGTON, AUTISM OR OTHER DISORDERS
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
CA2862076C (en) 2012-01-23 2020-04-21 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
RU2014139008A (ru) 2012-02-29 2016-04-20 Б. Браун Мельзунген Аг Гормонсодержащая эмульсия, содержащая фосфолипиды криля
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
DK2925327T3 (da) 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
ES2618421T3 (es) 2013-01-29 2017-06-21 Aptinyx Inc. Moduladores espiro-lactama del receptor NMDA y usos de los mismos
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
SG11201505937SA (en) 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596B1 (en) 2013-01-29 2023-12-06 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
LT3514158T (lt) 2013-01-29 2023-02-10 Aptinyx Inc. Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
DK3033350T3 (da) 2013-08-12 2021-08-30 Univ Emory Progesterone fosfatanaloger og anvendelser relateret dertil
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
TWI798173B (zh) 2016-03-08 2023-04-11 美商賽吉醫療公司 神經活性類固醇，其組合物及用途
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
KR102538803B1 (ko) 2016-08-01 2023-06-01 앱티닉스 인크. 스피로-락탐 nmda 조정제 및 그의 사용 방법
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3918336A1 (en) * 2019-01-31 2021-12-08 University of Geneva Prospective markers in traumatic brain injury (tbi)
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20230190709A1 (en) * 2021-12-02 2023-06-22 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
JPH03500049A (ja) 1987-08-25 1991-01-10 ジー、ケルビン・ダブリュー ストレス、不安および発作活性の緩和のための組成物および方法
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
CZ297860B6 (cs) * 1993-01-19 2007-04-18 Endorecherche Inc. Pouzití prekursoru pohlavního steroidu pro prípravu farmaceutického prostredku
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5837544A (en) * 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
AU725214B2 (en) * 1995-06-06 2000-10-05 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
DE69632569T2 (de) * 1995-06-09 2005-08-18 Euroceltique S.A. Formulierungen und verfahren für eine verlängerte lokalanästhesie
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
JP2000513336A (ja) 1996-05-22 2000-10-10 ディバーシファイド ファーマシューティカルズ，インコーポレーテッド 薬物の経皮送達のための組成物、方法及びデバイス
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
AU739146B2 (en) 1997-05-02 2001-10-04 Wyeth Pregnan-3-ol-20-ones
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
EP1871382B1 (en) * 2005-03-24 2011-08-17 Emory University Methods for the treatment of central nervous system injury via a tapered administration of progesterone
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury

Also Published As

Publication number Publication date
WO2006102644A2 (en) 2006-09-28
DE602006020353D1 (de) 2011-04-07
US20090325920A1 (en) 2009-12-31
EP1868614B1 (en) 2012-08-08
AU2006226811A1 (en) 2006-09-28
US8614203B2 (en) 2013-12-24
CA2601715C (en) 2012-10-16
PT1868614E (pt) 2012-11-23
US20120289491A1 (en) 2012-11-15
JP2008534515A (ja) 2008-08-28
WO2006102596A3 (en) 2007-01-18
HK1128242A1 (en) 2009-10-23
JP2014055183A (ja) 2014-03-27
CY1111478T1 (el) 2015-08-05
CA2602950C (en) 2012-10-30
HRP20110198T1 (hr) 2011-04-30
JP2008534512A (ja) 2008-08-28
HRP20120688T1 (hr) 2012-09-30
DK2030622T3 (da) 2011-05-02
DK1868614T3 (da) 2012-11-12
EP2431042A1 (en) 2012-03-21
CY1113253T1 (el) 2016-04-13
AU2006226811B2 (en) 2010-11-25
WO2006102596A2 (en) 2006-09-28
ATE499104T1 (de) 2011-03-15
PL2030622T3 (pl) 2011-07-29
JP5394059B2 (ja) 2014-01-22
AU2006226774B2 (en) 2010-12-02
EP2030622A1 (en) 2009-03-04
JP2011225629A (ja) 2011-11-10
JP5295755B2 (ja) 2013-09-18
HK1112581A1 (en) 2008-09-12
EP2030622B1 (en) 2011-02-23
JP5496407B2 (ja) 2014-05-21
WO2006102644A9 (en) 2006-11-23
ES2428313T3 (es) 2013-11-07
US20090221544A1 (en) 2009-09-03
WO2006102644A3 (en) 2007-03-01
CA2601715A1 (en) 2006-09-28
EP2494976A1 (en) 2012-09-05
RS52471B (en) 2013-02-28
EP1871382A2 (en) 2008-01-02
HK1112579A1 (en) 2008-09-12
AU2006226774A1 (en) 2006-09-28
EP2431042B1 (en) 2013-06-26
ES2392454T3 (es) 2012-12-10
EP1871382B1 (en) 2011-08-17
CA2602950A1 (en) 2006-09-28
PT2030622E (pt) 2011-06-02
EP1868614A2 (en) 2007-12-26
ATE520404T1 (de) 2011-09-15
US20120245133A1 (en) 2012-09-27
JP2013234191A (ja) 2013-11-21

Similar Documents

Publication Publication Date Title
HK1112579A1 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
WO2008033792A3 (en) Repetitive transcranial magnetic stimulation for movement disorders
CA2875824C (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
WO2012106444A3 (en) Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia
MY202377A (en) Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)
EP4269439A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
TN2019000332A1 (en) Methods of treating pediatric cancers
HK1095285A1 (en) Benzamidine derivatives for treatment and prevention of mucositis
WO2016043874A3 (en) Combination therapy for treating cancer
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004012662A3 (en) Improved treatment of cancer with glutamine
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
SI1913947T1 (sl) Kombinirana terapija za zdravljenje raka
AR066778A1 (es) Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
WO2018060528A3 (en) Therapeutic protein
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2017197249A3 (en) METHODS OF TREATING HYPER-BILIRUBINEMIA USING STANNSOPORFIN AND PHOTOTHERAPY
Fitzgibbon et al. Combined cerebral and peripheral treatments for pain: A commentary on Hazime et al.
GB202218314D0 (en) Vitamin a for use in the treatment of traumatic brain injury
Peter Celecoxib/thalidomide/temozolomide
UA77025U (ru) Способ лечения больных с черепно-мозговой травмой